Zealand Pharma A/S, headquartered in Søborg near Copenhagen, Denmark, is a biotechnology company dedicated to developing peptide-based medicines for metabolic and rare diseases such as diabetes, obesity, and short bowel syndrome. Established in 1997, the company successfully brought two drugs to market and has multiple candidates for late-stage development. Employing nearly 200 people and maintaining a subsidiary in the US, Zealand Pharma collaborates with major pharmaceutical companies, including Sanofi and Boehringer Ingelheim, to advance its innovative treatments. Recent investments have strengthened its financial position, enabling continued growth and development.